Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2017-10-19 Earnings Release
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Earnings Release 2017
Earnings Release Classification · 1% confidence The document text contains detailed financial figures, including 'Nettoomsättning' (Net Sales), 'EBITDA', 'Resultat per aktie' (Earnings per share), and cash flow metrics, specifically broken down for 'kv 3 2017' (Q3 2017) and year-to-date ('ack 2017' or 'januari – september'). It includes a 'VD-kommentar' (CEO comment) and a section titled 'Finansiell information och redogörelse från verksamheten' (Financial information and statement of operations). The presence of quarterly financial data, comprehensive operational review, and forward-looking statements strongly indicates a periodic financial report covering less than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). The document also mentions an upcoming 'Bokslutskommuniké 2017' (Year-end report) and 'Årsredovisning' (Annual Report), confirming this document is not the annual report (10-K). Q3 2017
2017-10-19 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the third quarter (Q3) of 2017, containing detailed financial statements, management commentary, revenue breakdowns, and operational highlights. It is clearly an interim financial report rather than an announcement or a summary, as it provides substantive financial data and analysis for the period ending September 30, 2017. Q3 2017
2017-10-19 English
Orexo signs asset purchase agreement with Gesynta Pharma AB for OX-MPI
M&A Activity Classification · 1% confidence The document is a press release announcing a specific corporate transaction: Orexo signing an asset purchase agreement with Gesynta Pharma AB for the OX-MPI program. This type of announcement, detailing a significant business development like an acquisition or divestiture of assets, falls under the category of Merger & Acquisition (M&A) activity or a major corporate transaction. Based on the provided definitions, 'M&A Activity (Code: TAR)' is the most appropriate classification for an announcement regarding a takeover bid or merger proposal, which an asset purchase agreement closely resembles in terms of corporate restructuring and transaction nature. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific, material business event.
2017-10-02 English
Orexo tecknar förvärvsavtal med Gesynta Pharma AB avseende OX-MPI
M&A Activity Classification · 1% confidence The document is a press release dated October 2, 2017, announcing that Orexo AB has signed an acquisition agreement with Gesynta Pharma AB regarding the OX-MPI program. This involves the transfer of assets related to a drug candidate (BI1029539) and future revenue sharing. This type of announcement, detailing a corporate transaction, asset transfer, or financing arrangement, fits best under the 'Capital/Financing Update' category, as it concerns a significant change in the company's asset portfolio and future revenue streams through a deal structure. While it is a corporate announcement, it is more specific than a general RNS filing. It is not an earnings release (ER), an annual report (10-K), or a management discussion (MDA). It is a specific transaction announcement, aligning closely with 'CAP' (Capital/Financing Update) which covers fundraising and capital structure changes, which asset acquisition/divestiture often falls under in a broad sense, or potentially 'RNS' if CAP is strictly interpreted as equity/debt financing. Given the nature of acquiring/divesting a drug program and structuring future payments, 'CAP' is the most appropriate fit among the specific options for corporate development activities that impact future value/structure, although 'RNS' is a strong secondary candidate if the transaction itself is not deemed 'financing'. However, since it details a major corporate transaction involving future financial rights, I will classify it as 'CAP'.
2017-10-02 Swedish
Positivt CHMP utlåtande för behandling av opioidberoende med Zubsolv® (buprenorfin och naloxon) i Europa
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding Zubsolv®. It details regulatory progress, partnership terms, and future expectations, but it is not a formal regulatory filing like a 10-K or an IR. It is an announcement about a regulatory milestone and commercial progress. Since it is a press release announcing a significant event (regulatory opinion) and not a full report, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but the focus here is regulatory/commercial news. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for a general corporate announcement of this nature that doesn't fit a more specific category like DIV, CAP, or ER (which usually focuses on financial results). The document length (6660 chars) is substantial enough that it's more than just a brief notice, but it is still an announcement. Revisiting the definitions: It is not an ER (Earnings Release), AR (Audit Report), CT (Call Transcript), or IP (Investor Presentation). It is a corporate announcement regarding regulatory progress. RNS (Regulatory Filings) is the best fit for general, non-financial-result-specific regulatory news announcements.
2017-09-15 Swedish
CHMP positive opinion for opioid dependence treatment with Zubsolv® (buprenorphine and naloxone) in Europe
Regulatory Filings Classification · 1% confidence The document is a press release announcing a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding a drug (Zubsolv) for opioid dependence treatment. It details a regulatory milestone, partnership updates, and future expectations (final decision in Q4 2017). This type of announcement, which communicates a specific regulatory event or development rather than a comprehensive financial report (like 10-K or IR) or a general market update (like ER), fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial report (10-K, IR). Since it is a specific regulatory update, RNS is the most appropriate classification.
2017-09-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.